Korean Drug Past Earnings Performance
Past criteria checks 0/6
Korean Drug's earnings have been declining at an average annual rate of -0%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 10.2% per year.
Key information
-0.003%
Earnings growth rate
0.2%
EPS growth rate
Pharmaceuticals Industry Growth | 11.3% |
Revenue growth rate | 10.2% |
Return on equity | -6.4% |
Net Margin | -6.0% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Korean Drug (KOSDAQ:014570) Is Growing Earnings But Are They A Good Guide?
Feb 19Are Korean Drug's (KOSDAQ:014570) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 18Recent updates
Should You Be Adding Korean Drug (KOSDAQ:014570) To Your Watchlist Today?
Mar 11Korean Drug (KOSDAQ:014570) Is Growing Earnings But Are They A Good Guide?
Feb 19Korean Drug Co., Ltd.'s (KOSDAQ:014570) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Feb 01Is Korean Drug Co., Ltd. (KOSDAQ:014570) Popular Amongst Insiders?
Jan 11Can You Imagine How Jubilant Korean Drug's (KOSDAQ:014570) Shareholders Feel About Its 111% Share Price Gain?
Dec 24Here's Why I Think Korean Drug (KOSDAQ:014570) Might Deserve Your Attention Today
Dec 06Are Korean Drug's (KOSDAQ:014570) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 18Revenue & Expenses BreakdownBeta
How Korean Drug makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 81,375 | -4,917 | 29,441 | 0 |
30 Sep 23 | 82,179 | 3,561 | 19,460 | 0 |
30 Jun 23 | 83,004 | 5,450 | 19,560 | 0 |
31 Mar 23 | 81,140 | 12,657 | 19,590 | 0 |
31 Dec 22 | 79,984 | 11,809 | 19,111 | 0 |
30 Sep 22 | 82,376 | 12,055 | 18,238 | 0 |
30 Jun 22 | 79,302 | 9,828 | 17,917 | 0 |
31 Mar 22 | 76,360 | 9,443 | 18,131 | 0 |
31 Dec 21 | 74,466 | 9,042 | 18,529 | 0 |
30 Sep 21 | 70,083 | 7,392 | 18,318 | 0 |
30 Jun 21 | 68,689 | 7,266 | 18,584 | 0 |
31 Mar 21 | 69,292 | 9,261 | 17,008 | 0 |
31 Dec 20 | 66,789 | 7,360 | 16,530 | 0 |
30 Sep 20 | 64,992 | 9,240 | 16,609 | 0 |
30 Jun 20 | 62,074 | 7,199 | 16,139 | 0 |
31 Mar 20 | 59,542 | 3,295 | 16,983 | 0 |
31 Dec 19 | 55,529 | 3,895 | 16,872 | 0 |
30 Sep 19 | 55,397 | 4,937 | 16,593 | 0 |
30 Jun 19 | 53,584 | 6,685 | 16,383 | 0 |
31 Mar 19 | 52,491 | 7,256 | 16,053 | 0 |
31 Dec 18 | 52,028 | 6,562 | 15,841 | 0 |
30 Sep 18 | 52,959 | 3,793 | 15,765 | 0 |
30 Jun 18 | 55,085 | 3,932 | 16,423 | 0 |
31 Mar 18 | 55,792 | 4,726 | 16,827 | 0 |
31 Dec 17 | 55,403 | 4,683 | 16,682 | 0 |
30 Sep 17 | 56,051 | 5,289 | 16,735 | 0 |
30 Jun 17 | 54,666 | 5,070 | 16,165 | 0 |
31 Mar 17 | 54,063 | 4,987 | 15,833 | 0 |
31 Dec 16 | 55,308 | 5,050 | 15,795 | 0 |
30 Sep 16 | 51,223 | 2,561 | 14,870 | 0 |
30 Jun 16 | 50,101 | 2,396 | 14,594 | 0 |
31 Mar 16 | 47,908 | 1,680 | 14,415 | 0 |
31 Dec 15 | 47,391 | 1,774 | 14,357 | 0 |
30 Sep 15 | 45,583 | 2,394 | 14,589 | 0 |
30 Jun 15 | 45,944 | 2,188 | 14,542 | 0 |
31 Mar 15 | 46,379 | 2,265 | 14,710 | 0 |
31 Dec 14 | 45,392 | 2,151 | 14,356 | 0 |
30 Sep 14 | 45,482 | 1,514 | 15,166 | 0 |
30 Jun 14 | 43,993 | 1,003 | 15,060 | 0 |
31 Mar 14 | 42,038 | 768 | 14,942 | 0 |
31 Dec 13 | 41,555 | 709 | 14,850 | 0 |
30 Sep 13 | 41,132 | 962 | 15,202 | 0 |
30 Jun 13 | 41,120 | 1,037 | 15,460 | 0 |
Quality Earnings: A014570 is currently unprofitable.
Growing Profit Margin: A014570 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A014570 is unprofitable, and losses have increased over the past 5 years at a rate of 0% per year.
Accelerating Growth: Unable to compare A014570's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A014570 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (34.6%).
Return on Equity
High ROE: A014570 has a negative Return on Equity (-6.38%), as it is currently unprofitable.